etodolac has been researched along with Rheumatic Diseases in 5 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 6.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 2.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| "Etodolac has been shown to be clinically effective with a low incidence of adverse effects." | 2.37 | Therapeutic choices for rheumatic disorders. ( Hughes, G, 1988) |
| "The costs of treating gastroduodenal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are shown to increase the total cost of NSAID treatment to the Assurance-Maladie, the French national health insurance system." | 1.28 | The economic consequences of NSAID-induced gastropathy: the French context. ( de Pouvourville, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reginster, JY | 1 |
| Franchimont, P | 1 |
| de Pouvourville, G | 1 |
| Mauviel, A | 2 |
| Redini, F | 2 |
| Loyau, G | 2 |
| Pujol, JP | 2 |
| Hughes, G | 1 |
2 reviews available for etodolac and Rheumatic Diseases
| Article | Year |
|---|---|
Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Topics: Acute Disease; Adult; beta-Cyclodextrins; Controlled Clinical Trials as Topic; Cyclodextrins; Diclof | 1993 |
Therapeutic choices for rheumatic disorders.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Etodolac; Humans; Indoleacetic Acid | 1988 |
3 other studies available for etodolac and Rheumatic Diseases
| Article | Year |
|---|---|
The economic consequences of NSAID-induced gastropathy: the French context.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost of Illness; Diclofenac; Duodenal Ulce | 1992 |
Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. I: Collagen synthesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Cells, Cultured; Collagen; E | 1990 |
Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. II: Glycosaminoglycan synthesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Cells, Cultured; Etodolac; E | 1990 |